Abstract
Introduction: The aim was to evaluate the prognostic value of altered Cyclin A2 (CCNA2) gene expression in upper tract urothelial carcinoma (UTUC) and to assess its predictive potential as a prognostic factor for overall survival (OS) and disease-free survival. Methods: 62 patients who underwent surgical treatment for UTUC were included. Gene expression of CCNA2, MKI67, and p53 was analyzed by quantitative reverse transcriptase polymerase chain reaction. Survival analyses were performed using the Kaplan-Meier method and the log-rank test. For Cox regression analyses, uni- and multivariable hazard ratios were calculated. Spearman correlation was used to analyze correlation of CCNA2 expression with MKI67 and p53. Results: The median age of the cohort was 73 years, and it consisted of 48 males (77.4%) and 14 females (22.6%). Patients with high CCNA2 expression levels showed longer OS (HR 0.33; 95% CI: 0.15–0.74; p = 0.0073). Multivariable Cox regression analyses identified CCNA2 overexpression (HR 0.37; 95% CI: 0.16–0.85; p = 0.0189) and grading G2 (vs. G3) (HR 0.39; 95% CI: 0.17–0.87; p = 0.0168) to be independent predictors for longer OS. CCNA2 expression correlated positively with MKI67 expression (Rho = 0.4376, p = 0.0005). Conclusion: Low CCNA2 expression is significantly associated with worse OS. Thus, CCNA2 might serve as a potential biomarker in muscle-invasive UTUC and may be used to characterize a subset of patients having an unfavorable outcome and for future risk assessment scores.
Journal Section:
Research Article
References
1.
Rouprêt
M
, Babjuk
M
, Compérat
E
, Zigeuner
R
, Sylvester
RJ
, Burger
M
, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update
. Eur Urol
. 2018
;73
(1
):111
–22
. .2.
Soria
F
, Shariat
SF
, Lerner
SP
, Fritsche
HM
, Rink
M
, Kassouf
W
, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
. World J Urol
. 2017
;35
(3
):379
–87
. .3.
Leow
JJ
, Chong
KT
, Chang
SL
, Bellmunt
J
. Upper tract urothelial carcinoma: a different disease entity in terms of management
. ESMO open
. 2016
;1
(6
):e000126
. .4.
Green
DA
, Rink
M
, Xylinas
E
, Matin
SF
, Stenzl
A
, Roupret
M
, et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins
. J Urol
. 2013
;189
(4
):1214
–21
. .5.
Hassler
MR
, Bray
F
, Catto
JWF
, Grollman
AP
, Hartmann
A
, Margulis
V
, et al. Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature
. Eur Urol
. 2020
;78
(2
):209
–20
. .6.
Ploussard
G
, Xylinas
E
, Lotan
Y
, Novara
G
, Margulis
V
, Rouprêt
M
, et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma
. Eur Urol
. 2015
;67
(4
):803
–12
. .7.
Gayed
BA
, Bagrodia
A
, Gaitonde
M
, Krabbe
LM
, Meissner
M
, Kapur
P
, et al. Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: preliminary results
. Urol Oncol
. 2015
;33
(1
):18.e21
–6
. .8.
Lughezzani
G
, Burger
M
, Margulis
V
, Matin
SF
, Novara
G
, Roupret
M
, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature
. Eur Urol
. 2012
;62
(1
):100
–14
. .9.
Mbeutcha
A
, Rouprêt
M
, Kamat
AM
, Karakiewicz
PI
, Lawrentschuk
N
, Novara
G
, et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review
. World J Urol
. 2017
;35
(3
):337
–53
. .10.
Kriebel
S
, Schmidt
D
, Holdenrieder
S
, Goltz
D
, Kristiansen
G
, Moritz
R
, et al. Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer
. PloS one
. 2015
;10
(1
):e0117284
. .11.
Montalbo
R
, Izquierdo
L
, Ingelmo-Torres
M
, Lozano
JJ
, Capitán
D
, Alcaraz
A
, et al. Prognostic value of circulating microRNAs in upper tract urinary carcinoma
. Oncotarget
. 2018
;9
(24
):16691
–700
. .12.
Krabbe
LM
, Bagrodia
A
, Lotan
Y
, Gayed
BA
, Darwish
OM
, Youssef
RF
, et al. Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma
. J Urol
. 2014
;191
(1
):28
–34
. .13.
Pagano
M
, Pepperkok
R
, Verde
F
, Ansorge
W
, Draetta
G
. Cyclin A is required at two points in the human cell cycle
. EMBO J
. 1992
;11
(3
):961
–71
. .14.
Yam
CH
, Fung
TK
, Poon
RY
. Cyclin A in cell cycle control and cancer
. Cell Mol Life Sci
. 2002
;59
(8
):1317
–26
. .15.
Ohashi
R
, Gao
C
, Miyazaki
M
, Hamazaki
K
, Tsuji
T
, Inoue
Y
, et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas
. Anticancer Res
. 2001
;21
(1b
):657
–62
.16.
Chao
Y
, Shih
YL
, Chiu
JH
, Chau
GY
, Lui
WY
, Yang
WK
, et al. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma
. Cancer Res
. 1998
;58
(5
):985
–90
.17.
Bukholm
IR
, Bukholm
G
, Nesland
JM
. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas
. Int J Cancer
. 2001
;93
(2
):283
–7
. .18.
Volm
M
, Koomägi
R
, Mattern
J
, Stammler
G
. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas
. Br J Cancer
. 1997
;75
(12
):1774
–8
. .19.
Su
TT
, Jaklevic
B
. DNA damage leads to a Cyclin A-dependent delay in metaphase-anaphase transition in the Drosophila gastrula
. Curr Biol
. 2001
;11
(1
):8
–17
. .20.
Wang
Y
, Prives
C
. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases
. Nature
. 1995
;376
(6535
):88
–91
. .21.
Zhang
T
, Prives
C
. Cyclin a-CDK phosphorylation regulates MDM2 protein interactions
. J Biol Chem
. 2001
;276
(32
):29702
–10
. .22.
Worst
TS
, Weis
CA
, Stöhr
R
, Bertz
S
, Eckstein
M
, Otto
W
, et al. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making
. Sci Rep
. 2018
;8
(1
):14383
. .23.
Rinaldetti
S
, Wirtz
RM
, Worst
TS
, Eckstein
M
, Weiss
CA
, Breyer
J
, et al. FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes
. Oncotarget
. 2017
;8
(29
):47595
–606
. .24.
Hall
M
, Peters
G
. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
. Adv Cancer Res
. 1996
;68
:67
–108
. .25.
Yasmeen
A
, Berdel
WE
, Serve
H
, Müller-Tidow
C
. E- and A-type cyclins as markers for cancer diagnosis and prognosis
. Expert Rev Mol Diagn
. 2003
;3
(5
):617
–33
. .26.
Girard
F
, Strausfeld
U
, Fernandez
A
, Lamb
NJ
. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts
. Cell
. 1991
;67
(6
):1169
–79
. .27.
Pagliuca
FW
, Collins
MO
, Lichawska
A
, Zegerman
P
, Choudhary
JS
, Pines
J
. Quantitative proteomics reveals the basis for the biochemical specificity of the cell-cycle machinery
. Mol Cell
. 2011
;43
(3
):406
–17
. .28.
Gong
D
, Pomerening
JR
, Myers
JW
, Gustavsson
C
, Jones
JT
, Hahn
AT
, et al. Cyclin A2 regulates nuclear-envelope breakdown and the nuclear accumulation of cyclin B1
. Curr Biol
. 2007
;17
(1
):85
–91
. .29.
Wu
S
, Chen
J
, Dong
P
, Zhang
S
, He
Y
, Sun
L
, et al. Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma
. BMC Cancer
. 2014
;14
(1
):836
. .30.
Kanakkanthara
A
, Jeganathan
KB
, Limzerwala
JF
, Baker
DJ
, Hamada
M
, Nam
HJ
, et al. Cyclin A2 is an RNA binding protein that controls Mre11 mRNA translation
. Science
. 2016
;353
(6307
):1549
–52
. .31.
Dong
S
, Huang
F
, Zhang
H
, Chen
Q
. Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarcinoma
. Biosci Rep
. 2019
;39
(2
). .32.
Gan
X
, Lin
X
, He
R
, Lin
X
, Wang
H
, Yan
L
, et al. Prognostic and clinicopathological significance of downregulated p16 expression in patients with bladder cancer: a systematic Review and meta-analysis
. Dis Markers
. 2016
;2016
:5259602
. 33.
Shariat
SF
, Tokunaga
H
, Zhou
J
, Kim
J
, Ayala
GE
, Benedict
WF
, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer
. J Clin Oncol
. 2004
;22
(6
):1014
–24
. .© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
